Enhancement of yellow fever virus neurovirulenee for mice by specific antibody was studied with the French neurotropic vaccine strain. Experimental conditions for enhancement required mice between 14 and 40 days old and intraperitoneal administration of a selected monoclonal antibody 24 h before or up to 72 h after intracerebral virus challenge. Virus infectivity titrations were similar in brains of antibody-treated and untreated mice. Virus recovered from brains of mice with enhanced viral infections was neither qualitatively nor quantitatively different from standard virus. Humorat immune responses in enhanced infections were normal, macrophages did not become infected and viraemia was not significant. Both hydrocortisone treatment and complement depletion with cobra venom resulted in prolongation of mouse survival times but virulence enhancement persisted. Antithymocyte serum had no effect on enhancement although it reduced the humoral immune response. It is proposed that virulence enhancement is due to the combined effects of virus-specific antibody on infected cells, complement-mediated cytolysis and resultant host anti-cellular activity. There is no analogy between mechanisms effecting increased arbovirus growth in vitro in the presence of specific antibody and increased yellow fever virus neurovirulence in vivo after parenteral administration of antibody.
INTRODUCTION
first described enhancement by antibody of virus infectivity in vitro; a comparable phenomenon was later shown to be mediated by binding of infectious virusantibody complexes to cellular Fc and complement receptors (Peiris et al., 1981 ; Cardosa et al., 1983) . There is no general agreement on a parallel phenomenon in vivo. However, Halstead et al. (1973) reported increased viraemia in monkeys sequentially infected with dengue virus or when antibody was given before the virus; increased susceptibility to dengue 2 virus was also seen in people vaccinated against yellow fever (YF). Others reported "early death" syndrome in some humans (Sikes et al., 1971) or in animals (Blancou et al., 1980; Prabhakar & Nathanson, 1981) partially protected against rabies, and Weiss & Scott (1981) increased the virulence of feline peritonitis virus in kittens which had received specific antibody passively.
Recently, reported early death in mice given YF virus combined with certain monoclonal antibodies (MAbs) but the mechanisms of immune enhancement were not defined. In this paper we show that the process results from specific reactions between virus and antibody in the infected brain. It is not mediated through Fc and complement receptor-bearing macrophages.
METHODS
Viruses. The French neurotropic vaccine strain of YF virus (FNV) was obtained from CAMR, Porton Down, Salisbury, U.K. For stock virus, Vero cells were infected at an input multiplicity of 0.01 p.f.u./cell and incubated 0000-7797 © 1987 SGM until significant c.p.e, had developed. The supernatant medium was clarified by centrifugation at 3000 g for 15 min and aliquots were stored at -70 °C.
Cells and media. Vero cells were subcultured in L15 medium supplemented with 5~ foetal calf serum, 10~ tryptose phosphate broth and 100 units/ml of penicillin and streptomycin (growth medium).
MAbs. Preparation and characteristics of MAb 427 and MAb 294 (control antibody against hepatitis B surface antigen) have been described previously (Gould et al., 1985b; .
Anti-thymocyte serum. This was prepared in rabbits as described by Levey & Medawar (1966) . Mice and their treatment. Random bred 3 to 4 week old female Swiss mice (strain TO) were obtained from Tuck and Sons, Battlesbridge, U.K. Unless otherwise stated, passive transfer of antibody in the form of undiluted ascitic fluid was performed by intraperitoneal inoculation (0-1 ml) of the appropriate preparations either at the times indicated in the text, or immediately prior to virus challenge. Average survival time (AST) in days and S.E.M. was estimated at the end of each experiment. Different batches of mice infected with FNV varied slightly in survival time. Consequently, all experiments were controlled internally. Complement depletion of mice was achieved by intraperitoneal inoculation of 5 units cobra venom anti-complementary protein (Sigma) 24 h prior to virus challenge.
Depletion of circulating T cells was accomplished by intraperitoneal inoculation (0.5 ml) of anti-thymocyte serum 48 h and 24 h prior to virus challenge. To monitor T cell depletion, control mice treated similarly were given approximately 5 × l0 s sheep erythrocytes. They were bled on days 0, 5 and 12 post-injection. Twenty ~tl of each serum was serially diluted in isotonic saline in microtitre plates. Sheep cell haemagglutinins were determined in duplicate by addition of 20 ~tl of 2~ sheep erythrocytes to each microtitre well. Titres were recorded, erythrocytes resuspended, and 20 ~tl of 0.1 M-2-mercaptoethanol was added (Scott & Gershon, 1970) .
Hydrocortisone acetate (Sigma) was given intraperitoneally 24 h before virus challenge at a dose of 1.25 mg/mouse and subsequently on alternate days at 0.5 mg/mouse.
Immunofluorescence. Indirect immunofiuorescence tests were performed on infected Vero cells and cryostat sections of mouse brains using the biotin-streptavidin procedure (Gould et al., 1985a) .
Plaque reduction neutralization tests. Serial dilutions of MAb 427 were mixed with equal volumes of virus diluted to produce 50 plaques per Petri dish. The mixtures were incubated at 37 °C for 1 h and 0.5 ml samples inoculated onto Vero cells. After incubation at 37 °C for 1 h the cells were washed three times with L15 medium and 6 ml of medium containing 0-5 ~ agarose was added to each dish. The dishes were incubated at 37 °C for 7 days, fixed with 10~ formalin and stained with naphthalene black. The neutralizing titre of the antibody was the highest dilution that reduced plaque numbers by 50~.
RESULTS

Influence of mouse age on immune enhancement
MAb 427 or control MAb 294 was given intraperitoneaUy to groups of 10 mice ranging in age from 1 to 56 days. The mice were then each challenged intracerebrally with 1000 LDs0 of FNV virus. Mice were monitored daily and AST calculated at the end of the experiment. These experiments showed that enhancement of virulence did not occur in very young mice (1 to 9 days). However, significant enhancement (P < 0.01) was seen in mice 14 to 40 days old but not in those above this age ( Table 1 ). The experiment illustrates the effect of age on mouse susceptibility to virus infection and results for each age group can only be considered in terms of the internal controls. Failure to detect significant enhancement in older mice possibly reflects their longer survival times after paralysis appeared. Thus, the mean day of paralysis in the oldest age group still showed a significant difference between antibody-treated and control mice.
Effect of time of administration of antibody on enhancement
Either MAb 427 or control MAb 294 was given intraperitoneally to groups of 10 mice (21 to 28 days) at different times pre-or post-intracerebral challenge with FNV virus. Enhancement of virulence was significant (P < 0.01) at all times of antibody administration from 24 h pre-and up to 72 h post-infection (Table 2 ). In separate experiments, virus and antibody were mixed for 1 h at 37 °C and the mixtures were inoculated intracerebrally into mice. Enhancement was detected, the AST of these mice being indistinguishable from those described in the above experiments.
Titration of virus infectivity yields under enhancing conditions
Either MAb 427 or control MAb 294 was given intraperitoneally to mice which were then immediately challenged intracerebrally with virus. At daily intervals five individual 20~ brain suspensions from each experiment were prepared and titrated for virus. Titres in the brains increased rapidly reaching peak levels by day 4 post-infection. The presence in the mice of MAb 427 did not affect the amount of virus infectivity detected. There was no difference between control and antibody-treated mice in either the rate of increase or in the final virus titre (Fig. 1) .
YF virus virulence enhancement
In separate experiments, the titre of FNV was determined directly by intracerebral inoculation of serial virus dilutions in mice given MAb 427 or MAb 294 intraperitoneally. No significant differences were noted between titres of virus titrated in the presence or absence of enhancing antibody (106.50 LDs0 and 106.75 LDso/ml).
Tests to see wkether tke enkanced virus is a selected virulent variant
Individual 20% brain suspensions were prepared from mice used in enhancement experiments with MAb 427. Brains were harvested when mice became paralysed. Each virus suspension, at an input concentration of 1000 LDso, was then tested in conventional enhancement experiments with MAb 427 and control MAb 294. The results obtained with these viruses were identical to those reported with stock virus, demonstrating that variant viruses with increased virulence were not selected in the presence of MAb 427.
Neutralization tests on FNV, Asibi and 17D virus with MAb 427
Plaque reduction neutralization tests were carried out with FNV, two plaque variants of Asibi virus (ASspl and ASsp3) and a control YF 17D vaccine virus using serial twofold dilutions of MAb 427 mixed with equal volumes of virus diluted to produce 50 plaques per Petri dish (see Methods). MAb 427 was an inefficient neutralizer, giving 50% reduction of 17D plaques at a dilution of 1/20 and totally failing to neutralize either FNV or the two Asibi plaque variants. This contrasts with the previous observation by Buckley & Gould (1985) . Five brains were taken daily from each group. Fig. 3 . The log2 sheep red blood cell (SRBC) agglutinating antibody titres in normal mice (C)) and mice injected with anti-mouse thymocyte antibody (O). Sera were titrated at days 0, 5 and 12 after injection with 5 x 108 SRBC.
ASsp3 was neutralized by several other MAbs against YF virus. Interestingly, immune enhancement of the two Asibi variants by MAb 427 was identical. Thus, under the experimental conditions described here, the inability of MAb 427 to neutralize virus infectivity appears to be a critical factor for immune enhancement. It is also important to note that MAb 427 had the same titre (1/10000) by immunofluorescence when tested with any of these viruses.
Analysis of other factors associated with immune enhancement
A series of experiments was performed to assess both the characteristics of the enhancing antibody and the significance of the immunocompetence of the mice in virulence enhancement.
Heat inactivation of MAb 427 at 56 °C for 30 rain had no effect on its reduction of AST, neither did intraperitoneal inoculation of undiluted guinea-pig complement (0.5 ml/mouse). The monoclonal nature of MAb 427 was ensured by recloning the hybridoma cell line. Enhancement of virulence was produced in separate experiments with antibody from each of five clones.
The IgG fraction of MAb 427, separated with Protein A-Sepharose (Pharmacia) also enhanced viral virulence. This confirmed that the enhancement factor was an immunoglobulin.
Mouse sera, collected from FNV-infected mice at daily intervals, were analysed for anti-FNV antibodies by indirect immunofluorescence with FNV-infected Vero cells. Antibody was detected at 3 days post-infection at a titre of 1/10 and reached 1/40 on day 5. This showed that infected mice respond immunologically to F N V infection.
Peritoneal macrophages were collected from FNV-infected mice at daily intervals. Fig. 3 . The log, sheep red blood cell (SRBC) agglutinating antibody titres in normal mice (O) and mice injected with anti-mouse thymocyte antibody (0). Sera were titrated at days 0, 5 and 12 after injection with 5 × 10 s SRBC.
washed in phosphate-buffered saline and resuspended at a concentration of 1 x 107 cells per ml. After sonication for 30 s at 4 °C the fragmented suspensions were tested for infectious virus by titration in Vero cells (Gould et al., 1985b) . Virus was barely detectable despite very high infectious yields from appropriate brains at the later stages (see Fig. 1 ). Separate suspensions of macrophages from infected mice were analysed directly for presence of FNV antigen by indirect immunofluorescence using MAb 427. There was no fluorescence in the macrophages.
Examination of brains for an immunopathological reaction
Brains from FNV-infected or uninfected mice either with or without MAb 427 treatment were sectioned, stained with haematoxylin and eosin and examined microscopically. From day 4 post-infection lymphocytic infiltration, demyelination, oedema and perivascular cuffing were clearly present in brains of antibody-treated, FNV-infected mice. These histological changes were less marked in the brains of infected mice which had not received antibody.
Indirect immunofluorescence microscopy was also performed on acetone-fixed sections of these brains with a high titre MAb (813) prepared against YF virus (Gould et al., 1985 b) . By day 4 post-infection a high proportion of brain cells contained virus-specific antigen (Fig. 2a, b) . This proportion of fluorescent cells appeared to be similar in both MAb 427-treated and untreated brains. There was also no obvious difference in the rate at which antigen-positive cells appeared in these two systems; both showed a few infected cells on the second day after infection and these increased in number daily.
The immunocompetence of groups of mice was compromised with a variety of treatments given intraperitoneally (see below); one group of mice received 5 units of cobra venom anticomplementary protein per mouse. This led to a decrease of serum complement from 0.75 mg/ml to 0.15 mg/ml (measured on day 4 post-infection) by radial immunodiffusion assays with anticomplement antibody. A second group of mice received 0.5 ml of rabbit anti-mouse thymocyte serum at 48 and 24 h pre-infection. This temporarily destroyed the capacity to produce serum antibody (Fig. 3) . A third group of mice was given 1.25 mg per mouse of hydrocortisone acetate 24 h before virus challenge and 0.5 mg per mouse on subsequent alternate days until completion of the experiment. In general, hydrocortisone exhibits anti-inflammatory and/or immunosuppressive effects (for review, see Claman, 1975) .
Mice were given MAb 427 or control MAb 294 and infected with FNV virus. Destruction ofT cells did not make a significant difference to immune enhancement of FNV virus virulence (Table 3) , although susceptibility of mice to FNV infection was increased. However, hydrocortisone significantly increased mouse AST (P < 0.01) although enhancement remained significant (P < 0.01). Hydrocortisone had no effect on control mice treated with MAb 294. Results with complement-depleted mice also had two components: a significant (P < 0-05) increase in time to death was seen in mice given enhancing antibody and cobra venom, but enhancement was still significant (P < 0.01) when compared with the infected controls. Cobra venom had no effect on AST of control mice treated with MAb 294. Thus MAb 427, complement and other host defence mechanisms, but not T cell-dependent responses, each appear to play a contributory role in enhancing FNV neurovirulence.
DISCUSSION
We have previously shown that YF virus neurovirulence in mice is enhanced in the presence of MAb . The present paper was concerned with possible mechanisms leading to enhancement. Unlike antibody-dependent enhancement in vitro which is mediated through Fc and complement receptors (Peiris et al., 198 l ; Cardosa et al., 1983) , increased virus titres were not detected in mice that showed early death, implying a different mechanism for enhancement in vivo.
Early death occurred even in mice treated with antibody at 3 days post-infection. Thus, it is unlikely that increased efficiency of infection was responsible for enhancement. The importance of the antibody isotype is not yet known; however, the enhancing MAbs were of subclasses IgG1 and IgG2a and other antibodies of the same subclasses and with similar molecular specificities for the envelope (E) protein of YF virus did not produce enhancement under the experimental conditions described. Why the phenomenon occurred only in mice above 14 days old is not entirely clear but it is known that at this age, emerging lymphocyte and macrophage interaction functions as well as other factors, such as the deposition of myelin, can alter the susceptibility of mice to YF virus infection . No evidence ofmacrophage infection or invasion was seen but histologically the effect of enhancing antibody on the brain was to destroy cells, induce perivascular cuffing, oedema and demyelination. Such changes might result from host responses to antibody-induced cytolysis of infected cells or the formation of immune complexes as the result of antigenic modulation, capping and stripping (Oldstone et al., 1980) . Complement depletion, using cobra venom, did not totally prevent enhancement even though there was a significant increase in time to death of MAb 427-treated, complement-depleted mice. Complement therefore appears to contribute to enhancement of virulence but is unlikely to be wholly responsible for early death. Similarly, hydrocortisone treatment decreased the extent of enhancement without preventing it. Thus, host responses to injured tissue may be increased during enhancement but are not totally responsible for the phenomenon. On the other hand, depletion of T cell populations using anti-mouse thymocyte antibody (Doenhoff & Leuchars, 1977) did not significantly affect enhancement, ruling out the possibility that it was T cell-mediated. Nevertheless, anti-mouse thymocyte antibody did increase the susceptibility of the mice to FNV virus infection by shortening the time to death. This supports the evidence of Bradish et al. (1980) that T cells play an important role in the regulation of the expression of virulence by YF viruses.
We have previously shown by indirect immunofluorescence that antibodies against E protein will label infected cell surfaces and attach to released virions in the extracellular spaces (Gould et al., 1985 b) . MAb 427 also protects mice against infection with vaccine strains of YF virus that are of relatively low virulence. However, MAb 427 does not protect mice against more virulent strains of YF virus . This is consistent with results presented above which show that MAb 427 neutralizes YF 17D infectivity, albeit poorly, but not FNV or two plaque variants of Asibi virus differing from each other in their susceptibility to neutralization by other MAbs (Buckley & Gould, 1985) . A very large proportion of mouse brain cells become infected with FNV virus; therefore, very large quantities of virus and viral antigen must be present in the brain to become exposed to added MAb 427. This antibody fails to neutralize the virus and to protect mice from lethal infection presumably because for FNV the MAb 427 epitope is not in the critical neutralization site (Buckley & Gould, 1985) .
On the basis of competition blocking ELISA tests, the relative disposition of the MAb 427 epitope was shown to differ between YF 17D and YF AS viruses . Moreover, YF AS but not YF 17D virulence is enhanced in the presence of MAb 427 . This alteration of epitopic disposition may be biologically significant, and may lead to increased virulence of FN V and YF AS and to enhancement of virulence in the presence of appropriate non-neutralizing antibody.
It is therefore proposed that early death of mice arises from the interaction of MAb 427 with virus and viral antigen, perhaps at the infected cell surface. Such an interaction could lead to antibody-induced and/or complement-mediated lysis of the infected brain cells. Immune complex formation and increased host anti-cellular activity probably also contribute to early death. The facility with which MAb 427, as opposed to other antibodies, effects enhancement under the experimental conditions defined probably reflects its failure to produce protection or neutralization in mice infected with FNV or YF AS. Alternatively, it may reflect its ability to compete with and therefore to block the protective effect of the normal humoral response. On the other hand, other less virulent strains of YF virus are probably neutralized by MAb 427 resulting in lower infectivities in the brain and consequently no enhancement.
Finally, although it is realized that YF does not normally produce encephalitis in natural infections, it is known that immunity to YF virus can enhance human susceptibility to dengue 2 virus infection (Scott et al., 1983 ). Our mouse model may therefore prove useful in helping us to understand the pathogenicity of other flaviviruses.
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